Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

HonorHealth Research Institute, Scottsdale, Arizona

UC San Diego Moores Cancer Center, La Jolla, California

Stanford University, Stanford, California